Colorectal panel provides detailed cancer information
Answers from the Lab
New information about colorectal cancer has led to updated recommendations for testing and treatment. In this test specific episode of the "Answers From the Lab" podcast, Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' expanded colon panel, which provides enhanced information about prognosis, treatment options and a hereditary cancer syndrome.
"This new expanded panel allows us to address patient needs. It covers a larger number of genes and provides a greater amount of clinically actionable information," Dr. Graham says.
In addition to covering multiple gene mutations, the assay assesses for microsatellite instability and Lynch syndrome. Microsatellite instability is a biomarker for response to checkpoint inhibitor treatment. The American Society of Clinical Oncologists recommends that testing for Lynch syndrome — an inherited cancer syndrome — be performed for all people diagnosed with colorectal cancer.
The MayoComplete Colorectal Cancer Panel uses next generation sequencing and is suitable both for patients with cancer confined to the colon and for cases of metastatic colorectal cancer.
"Being able to address all these patient needs and gain so much useful information in a single assay will be very helpful," Dr. Graham says.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
This assay requires at least 20% tumor nuclei
For specimen preparation guidance, see Tissue Requirement for Solid Tumor Next-Generation Sequencing. In this document, the sizes are given as 4mm x 4mm x 10 slides as preferred: approximate/equivalent to 144 mm(2) and the minimum as 3mm x 1mm x 10 slides: approximate/equivalent to 36mm(2).
Note: The total amount of required tumor nuclei can be obtained by scraping up to 10 slides from the same block
Additional Information: Unused unstained slides will not be returned
Analytic time: 12 days
Days performed: Monday through Friday
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.